The goal of this retrospective single-center chart review is to establish the response rate, efficacy and safety of a single dose of intravitreal faricimab injection in real-world patients with aflibercept- and ranibizumab-resistant neovascular age-related macular degeneration.

Inclusion criteria

• Presence of neovascular age-related macular degeneration (AMD) in the study eye
• Previous treatment with minimum 6 consecutive, monthly aflibercept (Eylea®) injections in the study eye without optimal treatment response, defined as persisting intraretinal fluid or subretinal fluid or both on optical coherence tomography scans
• Subsequently, a sequential switch to ranibizumab (Lucentis®), with minimum 1 injection, also without optimal response
• Finally, a sequential treatment switch from ranibizumab to faricimab.

Exclusion criteria

• Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
• Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
• Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch

Patients with neovascular age-related macular degeneration (AMD)